Zhejiang Shapuaisi Pharmaceutical (603168.SH) obtained the drug registration certificate for sodium bromfenac eye drops.

21/01/2025

SAPAS (603168.SH) announcement, recently, the company has received approval from the National Medical Products Administration to issue bromfenac...

Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that recently, the company received the "Drug Registration Certificate" for the sodium bromfenac eye drops issued by the National Medical Products Administration. The sodium bromfenac eye drops approved this time are used for symptomatic treatment of inflammatory diseases of the external and anterior parts of the eye: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.

How did Goldman Sachs Group, Inc. (GS.US) achieve a complete victory in the Federal Reserve's annual stress test?

Guolian Minsheng Securities: Polysilicon sector may lead the completion of photovoltaic supply-side adjustments, focusing on top silicon material companies with cost advantages.

HK Stock Market Move | HENLIUS (02696) is now up over 3%. The company has obtained an EU GMP certificate and recently signed a license agreement with FBD.

How did Goldman Sachs Group, Inc. (GS.US) achieve a complete victory in the Federal Reserve's annual stress test?

Guolian Minsheng Securities: Polysilicon sector may lead the completion of photovoltaic supply-side adjustments, focusing on top silicon material companies with cost advantages.

HK Stock Market Move | HENLIUS (02696) is now up over 3%. The company has obtained an EU GMP certificate and recently signed a license agreement with FBD.